












1130Accelerated Bone Mineral Density Loss Occurs
with Similar Incidence and Severity, But with Different
Risk Factors, after Autologous versus Allogeneic
Hematopoietic Cell Transplantation
Song Yao,1 Shannon L. Smiley,1 Kathleen West,2 Dominick Lamonica,3 Minoo Battiwalla,1
Philip L. McCarthy, Jr.,1 Theresa Hahn1Bone mineral density (BMD) loss occurs commonly in patients after allogeneic hematopoietic cell transplan-
tation (HCT), primarily because of steroid use, but little is known about BMD change post-autologous HCT.
In a prospective study of 206 consecutive first HCT patients, we measured acute BMD change at the lumbar
spine and dual femur between baseline and day 1100, and evaluated risk factors for bone loss. Accelerated
BMD loss in this 4-month period occurred after both autologous and allogeneic HCTwith similar severity
(median, 0.03 g/cm2 versus 0.03 g/cm2 at the spine; 0.03 g/cm2 versus 0.05 g/cm2 at the femur, respectively).
This is equivalent to 7 to 17 years’ worth of bone loss by aging. Risk factors for BMD loss were different
between autologous and allogeneic HCT patients: lymphoma was associated with greater bone loss after
autologous HCT than myeloma, whereas higher steroid dose was the most significant risk factor after
allogeneic HCT. Multivariable risk models explained 11% to 30% of the variation in HCT-related BMD change.
Surprisingly, BMD loss post-autologous HCToccurred with similar incidence and severity to allogeneic HCT,
even in the absence of steroid use. Evaluation of clinical strategies to prevent and reverse HCT-related BMD
loss is necessary in both autologous and allogeneic HCT patients.
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Hematopoietic cell transplantation (HCT) cures
patients with otherwise fatal hematologic diseases [1],
making quality of life among survivors an increasingly
important issue to be addressed. Accelerated bone
mineral density (BMD) loss is a common complication
after both solid organ and stem cell transplantation,
characterized by rapid bone loss, which persists for
many years [2-8]. This accelerated premature bone
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doubles the fracture risk [9,10].
Our previous retrospective study demonstrated that
BMDlossoccurs frequently after allogeneicHCT,even
in the absence of steroid exposure, and that antiresorp-
tive bisphosphonate treatmentwas effective in reversing
thebone loss in osteoporotic patients [11]. Several other
studies have also demonstrated efficacy at reversing
BMD loss post-HCT with bisphosphonates [12-17];
however, vitaminDwith or without calcium suppleme-
ntation, and hormone replacement therapy have failed
to prevent or reverse bone loss [12,14,18,19].
Although risk factors for BMD loss after allogeneic
HCT with myeloablative (MA) conditioning have
been described [6,7], there are no data on the
incidence and severity of BMD loss after allogeneic
HCT with NMA or reduced-intensity conditioning
(RIC) regimens. Moreover, for patients undergoing
autologous HCT, BMD change has only been
reported in small series with inconsistent findings. In
a retrospective cross-sectional study of 68 autologous
HCT patients, 28% had osteopenia or osteoporosis
at the spine and 54% at the femur a median of 4.2 years
after transplant [20]. Another study of 10 autologous
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showed a nonsignificant reduction of BMD at the
spine (21.1%) but an increase at the femur (1.5%)
[21]. These results conflict with a prospective study
including both autologous and allogeneic HCT
patients, which reported a nonsignificant loss at the
spine (22.4%) and a significant BMD loss at the femur
(23.8%) at 3 months after transplant [22].
In the present study, we sought to compare the
incidence, severity, and risk factors for BMD loss
between autologous and allogeneic HCT patients.
Steroid exposure is infrequent after autologous
HCT, but shows a strong correlation with BMD loss
after allogeneic HCT; therefore, we hypothesized
that incidence and risk factors for accelerated BMD
may differ between these 2 HCT patient groups.MATERIALS AND METHODS
Patient Population
Beginning in January 2006 as part of routine clinical
care, dual-energy X-ray absorptiometry (DXA) scans
and serum levels of 25-hydroxyvitamin D (25-OHD),
parathyroid hormone (PTH), and calcium were pro-
spectively measured at baseline and day 1100 after
transplantation in patients undergoing autologous and
allogeneicHCTin theBlood andMarrowTransplanta-
tion Program at Roswell Park Cancer Institute (RPCI).
No vitamin D or routine calcium supplementation was
given during this timeperiod.Calcium replacementwas
only administered for critical values of ionized calcium
\1.19 mmol/L. By January 2009, a total of 206 adult
($18 years) patients underwent their first HCT, 197
(96%) of whom had a baseline DXA scan a median 20
days pre-HCT. The most common reason for not
obtaining a baseline DXA was because of the patient’s
weight exceeding the maximum limit of the DXA
scanner (300 pounds). Of those with a baseline DXA
scan, 146 (74%) had a second DXA scan a median 98
days post-HCT. The reasons for not obtaining a fol-
low-up DXA scan were because of early death or
relapsed disease (N 5 37) or unstable medical status
(N 5 14). This study was reviewed and approved as
a nontherapeutic protocol by the institutional review
board (IRB) at RPCI. All data presentations have been
deidentified.Autologous High-Dose Therapy and Allogeneic
Conditioning Regimens
High-dose therapy regimens before autologous
HCT varied by underlying disease, age and perfor-
mance status. In the 102 autologous HCT patients
with a baselineDXA scan, these regimens included: cy-
clophosphamide (C)1 carmustine (B)1 etoposide (V)
(N 5 37), 120-200 mg/m2 melphalan (M) (n 5 32),busulfan (Bu) 1 C (n 5 26), or total body irradiation
(TBI) based (N 5 7). Conditioning regimens before
allogeneic HCT also varied by underlying disease,
age, and performance status. MA regimens in the 95
allogeneic HCT patients with a baseline DXA scan in-
cluded: C1 1200-1350 cGyTBI (n5 16), Bu1C (n5
12) orV1TBI (n5 1). RIC regimens included: fludar-
abine (Flu) 1M (n 5 57) or Flu 1 C 6 other (n5 9).
Graft-versus-Host Disease (GVHD) Prophylaxis
and Treatment
Prophylaxis for GVHD varied by age, underlying
disease risk, donor relation, stem cell source, and pro-
tocol. In the 95 allogeneic HCT patients who had
a baseline DXA scan, these regimens included: tacroli-
mus (FK) 1 methotrexate (MTX) 1 mycophenolate
mofetil (MMF) (N 5 38), FK 1 MMF (N 5 29), FK
1MTX (n5 22), or other (N5 6). Tacrolimus levels
were checked twice weekly to maintain levels between
5 and 15 ng/mL. It was initially given intravenously
and converted to oral once patients tolerated oral med-
ication, and was tapered in the absence of GVHD be-
ginning at day 130 for high-risk disease or day 1100
for low-risk disease. MTX was dosed at 2.5, 5, or 10
mg/m2 and given on days11,13,166 day111, de-
pending on age, donor relation, stem cell source, and
underlying disease risk.
First-line treatment for acuteGVHD(aGVHD)was
escalation of calcineurin inhibitor to the maximum dose
tolerated by renal function and initiation ofmethylpred-
nisolone 2 mg/kg for 3 days. If there is no response after
72hoursof corticosteroids, additional treatmentwas ini-
tiated either through enrollment on a steroid-refractory
GVHD protocol or per the program’s standard operat-
ing procedure for GVHD treatment.
BMD Measurement
BMD at the lumbar spine (average of L2, L3, and
L4) and at the dual femur (average of 2 entire femora)
was quantified by DXA scans using a single GE
Lunar Prodigy scanner (GE Medical Systems, Pis-
cataway, NJ). The coefficient of variance was 0.94%
at the spine and 0.76% at the femur. To adjust for ran-
dom errors with repeated measurements, we defined
a ‘‘significant’’ change of BMD according to the crite-
ria recommended by the International Society of Clin-
ical Densitometry that the least significant change
between 2 consecutive DXA scans must exceed 2.77
times the coefficient of variance [23]. This translates
to a minimum change of 2.6% at the spine and 2.1%
at the femur in our study. In addition, we also annual-
ized BMD loss rates in our patients and compared
those to the expected normal rates in the general pop-
ulation between 20 and 89 years of age: 0.1% at the
spine and 0.3% at the femur in males and 0.4% at
the spine and 0.6% at the femur in females [24].
Table 1. Patient Characteristics of Those Who Had
a Baseline DXA Scan before Autologous and Allogeneic
Transplantation
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osteoporosis was classified by T-score following the
WHO criteria [25].Characteristics
Autologous
HCT (n 5 102)
Allogeneic
HCT (n 5 95)
Age at HCT (years) 57 (25-74) 45 (18-71)
Spine BMD at baseline (g/cm2) 1.24 (0.69-1.98) 1.20 (0.76-1.83)
Femur BMD at baseline (g/cm2) 1.04 (0.60-1.41) 1.07 (0.49-1.45)
Sex
Male 64 (63%) 37 (39%)
Female 38 (37%) 58 (61%)
Race
Non-Hispanic White 89 (87%) 90 (95%)
Other 13 (13%) 5 (5%)
Diagnosis
Acute leukemia 9 (9%) 59 (62%)
Lymphoma 61 (60%) 18 (19%)
Myeloma 32 (31%) 0
Other 0 18 (19%)
Disease status at HCT
CR1/untreated 42 (41%) 54 (67%)
CR+2/PIF/Relapse 60 (59%) 41 (33%)
Time from diagnosis to HCT
Within 6 months 11 (11%) 43 (45%)
6 months-1 year 36 (35%) 26 (27%)
>1 year 55 (54%) 26 (27%)
Stem cell source
Bone marrow 9 (9%) 17 (18%)
Peripheral blood 93 (91%) 78 (82%)
Conditioning regimen
Myeloblative 102 (100%) 29 (31%)
Reduced Intensity 0 57 (60%)
Nonmyeloblative 0 9 (9%)
GVHD prophylaxis regimen
CsA/MTX/FKMTX/FK — 27 (29%)
FK/MMF — 29 (31%)
FK/MTX/MMF 38 (40%)
Donor relation
Unrelated — 59 (62%)
Related — 36 (38%)
HLA matched
Mismatched — 21 (22%)
Matched — 74 (78%)
Acute GVHD
Grade 0-1 — 27 (34%)
Grade II-IV — 52 (66%)
BMD indicates bone mineral density; CR, complete remission; CsA,
cyclosporine; DXA, dual-energy X-ray absorptiometry; GVHD, graft-Statistical Analyses
Serum levels of calcium were adjusted for albumin
[26] and the cumulative steroid dose received between
the 2 DXA scans was calculated as prednisone equiva-
lents [27]. Due to variations in the length of time
between 2 DXA scans, all BMD changes were stan-
dardized to 100 days. Data in autologous and alloge-
neic HCT patients were analyzed separately. BMD
was analyzed as a continuous variable. The change in
BMDwas calculated and analyzed in all statistical tests
as (post-HCT BMD 2 baseline BMD), so BMD loss
resulted in a negative value and a gain in BMD resulted
in a positive value. For clarity, we present the absolute
value of the change in BMD in the tables and text and
indicate whether this was a loss or gain in BMD.
Nonparametric Wilcoxon rank test and McNe-
mar’s exact test were used for comparisons of continu-
ous and categoric variables between 2 DXA scans or
other univariate comparisons where appropriate. The
Pearson correlation test was used for linear correla-
tions. For multivariable analyses, dummy variables
were created for categorical variables, and linear re-
gression models were fitted. Factors with a P-value
#.10 in the univariate analyses were entered and eval-
uated by backward elimination in the multivariable
models, and those with a P-value\.05 were retained
in the final models. Coefficients of determination
(R2) were adjusted by the degrees of freedom and
used as a measure of the proportion of variance in
BMD change that can be explained by the clinical
risk factors. All analyses were 2-sided with type I error
of 0.05 and performed using SAS 9.1 (SAS Institute,
Cary, NC).versus-host disease; HLA, human leukocyte antigen; Mt, methotrexate;
M, melphalan; FK, tacrolimus; MMF, mycophenolate mefetil; PIF, primary
induction failure; HCT, hematopoietic cell transplantation.
For continuous variables, median (range) is presented. For categorical
variables, count (percent) is presented.RESULTS
Of 197 patients who had a baseline DXA scan, 102
(52%) were autologous and 95 (48%) were allogeneic
HCT patients (see Table 1). Plots of the change in
T-score between baseline and post-HCT DXA scans
are shown in Figure 1. At baseline, few patients had os-
teoporosis (4% at the spine and 3% at the femur) and
a number of patients had osteopenia (17% at the spine
and 20% at the femur). After transplantation, BMD in
most patients remained in the normal range; however,
the majority of patients experienced a significant BMD
loss at the spine (54%) or femur (79%). The rate of
osteoporosis remained low (5% at the spine and 6%
at the femur), but the rate of osteopenia was signifi-
cantly increased (26% at the spine and 28% at the
femur, P\ .001).Importantly, the trend of BMD loss after autolo-
gous HCT resembled that after allogeneic HCT. As
summarized in Table 2, BMD loss at the spine and
the femur were statistically significant in both autolo-
gous and allogeneic patients (P\ .0001). The magni-
tude of BMD loss at the spine was similar between
autologous and allogeneic HCT patients, although
BMD loss at the femur was significantly higher in the
allogeneic group than the autologous group. BMD
loss was dramatically accelerated following HCT: the
observed loss rate was 27- to 37-fold higher in the
autologous group and 46- to 60-fold higher in the al-
logeneic group than the expected loss rates with the
normal aging process in the general population. After
Figure 1. Change in T-score between baseline and post-HCT DXA scans by autologous (A) and allogeneic (B) HCT.
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BMD loss rate between the autologous and allogeneic
HCT groups became smaller and nonsignificant (32-
and 51-fold higher at the femur and spine, respectively,
in the autologous group). Within the 4-month period
between the baseline and day 1100 DXA scans, the
BMD loss seen in autologous and allogeneic HCT
patients was equivalent to aging their bones by 7 to
10 years and 13 to 17 years, respectively.Over half of the patients were vitamin D deficient
(25-OHD levels #20 ng/mL) at baseline (51%) and
the prevalence nonsignificantly increased post-HCT
(57%). However, there was no correlation between
vitamin D levels at baseline or post-HCT, or change
in vitamin D levels, with BMD changes at either the
spine or the femur.Most patients hadPTH levelswithin
the normal range (12-65 pg/mL) at baseline (73%) and
post-HCT (79%); the rate of hyperparathyroidism
Table 2. BMD Change between Baseline and Post-HCT DXA Scans by Autologous and Allogeneic Transplantation*
BMD Measures
Autologous HCT Allogeneic HCT
Spine, Median (IQR) Femur, Median (IQR) Spine, Median (IQR) Femur, Median (IQR)
BMD loss, adjusted to 100 days (g/cm2) 0.03 (0-0.05) 0.03 (0.01-0.05) 0.03 (0-0.08) 0.05 (0.04-0.08)
Annualized rate of BMD loss (%) 7 (0-14) 9 (5-18) 9 (0-19) 17 (13-27)
Ratio of observed/expected annual BMD loss rate (fold)† 37 (3-112) 27 (12-46) 60 (2-119) 46 (25-73)
Years aged by the BMD loss within 4 months after transplant 10 (1-31) 7 (3-13) 17 (1-33) 13 (7-20)
BMD indicates bone mineral density; DXA, dual-energy X-ray absorptiometry; IQR, interquartile range; HCT, hematopoietic cell transplantation.
*Changes in all BMD measures resulted in P < .0001 based on nonparametric tests.
†The expected annual BMD loss rate is 0.1% to 0.4% at the spine, and 0.3% to 0.6% at the femur, which varies by sex.
1134 Biol Blood Marrow Transplant 16:1130-1137, 2010S. Yao et al.was 23% at baseline and 18% post-HCT. There was
also no relationship between PTH levels and BMD
change. Despite the rapid bone loss, calcium levels in
most patients (94% at baseline and post-HCT)
remained within the normal range (8.8-10.2 mg/dL).
We examined a number of potential predisposing
risk factors present at HCT or associated with HCT
therapy for BMD loss by univariate analyses. Those
with a P-value#.10 are summarized in Table 3. There
were different risk factor profiles for BMD loss in au-
tologous and allogeneic patients. In allogeneic HCT
patients, steroid dose was most strongly correlated
with BMD loss at the spine (R 5 0.45, P 5 .0004)
and at the femur (R 5 0.32, P 5 .01). Length of stay
in the hospital and aGVHD were both associated
with BMD change; however, after controlling for ste-
roid dose, neither association remained. In addition,
higher weight at baseline was correlated with higher
BMD loss (R 5 0.26, P 5 .05 at the spine; R 5 0.24,
P-value 5 .06 at the femur); and whereas a higher
BMD at baseline was also correlated with BMD loss
(R 5 0.22, P 5 .09 at the spine; R 5 0.24, P 5 .06 at
the femur). Both weight and baseline BMD remained
significant after controlling for steroid dose.
In autologous HCT patients, there was no associ-




Risk factors present at HCT
Younger age at HCT (year) N.S.
Higher weight at baseline (kg) N.S.
Higher BMD at baseline (g/cm2) .02
Diagnosis (lymphoma versus myeloma and ALL/AML) .03
Longer time from diagnosis to HCT N.S.
Risk factors associated with HCT
Conditioning regimen (Cy/TBI/Bu/Cy versus other) .03
Longer length of stay in hospital (days) N.S.
Higher steroid dose (prednisone equivalent, g) N.S.
Acute GVHD (grade 2-4 versus 0-1) —
BMD indicates bone mineral density; Bu, busulfan; Cy, cyclophosphamide; GV
nonsignificant with P > .10; HCT, hematopoietic cell transplantation; TBI, total
enous leukemia.
P-values were derived from Pearson’s correlation test for continuous covariat
P # .10 in the univariate analysis were entered and evaluated by backward
considered in the univariate analysis, but resulted in P > .10 in all 4 BMD m
GVHD prophylaxis regimen, donor relation, HLA-match, and gender match.most consistent risk factor was underlying disease:
Hodgkin and non-Hodgkin lymphoma patients expe-
rienced a greater BMD loss than multiple myeloma
(MM) patients (median loss in BMD: 0.036 g/cm2 ver-
sus 0.020 g/cm2, P5 .03 at the spine; 0.037 g/cm2 ver-
sus 0.017 g/cm2, P 5 .04 at the femur, respectively).
High-dose therapy regimen before autologous HCT
was strongly correlated with diagnosis, and its associa-
tion with change in BMD was not independent. Also,
lymphoma patients received a significantly higher av-
erage daily steroid dose within the first 100 days
post-HCT than MM patients (mean dose 5 mg/day
versus 2 mg/day, respectively), although this exposure
was much lower than the mean daily steroid dose of 19
mg/day in allogeneic HCT patients. In addition,
younger age at HCT was correlated with BMD loss
at the femur (R5 0.31, P5 .004), but not at the spine
(R5 0, P5 .99). Similar to allogeneic patients, higher
BMD at baseline was associated with greater BMD loss
at the spine (R5 0.26, P5 .02) in autologous patients;
but the association was weak and nonsignificant at the
femur (R 5 0.13, P 5 .23).
Based on univariate analyses, multivariate models
were constructed to assess change in BMD (see
Table 4). These significant clinical risk factors explain
only a small proportion of the variance in BMDchangeoss in Autologous and Allogeneic HCT Patients
logous HCT Allogeneic HCT










HD, graft-versus-host disease; KPS, Karnofsky performance score; N.S.,
body radiation, ALL, acute lymphoblastic leukemia; AML, acute myelog-
es and Wilcoxon rank-sum test for categorical covariates. Factors with
elimination in the multivariate analysis (see Methods section). Factors
easures, included height, gender, disease status at HCT, KPS at HCT,
Table 4. Multivariable Models of BMD Loss by Autologous and Allogeneic HCT
BMD Loss Covariates P-Value R2 Adjusted* R2
Autologous HCT Spine Higher spine BMD at baseline, Hodgkin or non-Hodgkin lymphoma diagnosis .005 0.15 0.12
Femur Younger age at HCT, Hodgkin or non-Hodgkin lymphoma diagnosis .006 0.14 0.11
Allogeneic HCT Spine Higher weight, higher spine BMD at baseline, higher steroid dose <.0001 0.33 0.30
Femur Higher weight, higher femur BMD at baseline, higher steroid dose .003 0.21 0.17
BMD indicates bone mineral density; HCT, hematopoietic cell transplantation.
*R2 was adjusted based on the degrees of freedom.
Biol Blood Marrow Transplant 16:1130-1137, 2010 1135BMD Loss in Autologous and Allogeneic HCT Patientsafter autologous HCT (adjusted R25 0.12 at the spine
and adjusted R25 0.11 at the femur). Although steroid
dose is a strong risk factor for BMD change after
allogeneic HCT, steroids, baseline weight, and BMD
explain only 30% of variance in BMD change at the
spine and 17% at the femur.DISCUSSION
Our study describes a significant BMD loss in the
majority of patients after autologous HCT, which is
independent of steroid use and of similar severity to
that seen after allogeneic HCT. Corticosteroids can
be used as an antiemetic or for treatment of complica-
tions such as interstitial pneumonitis and engraftment
syndrome after autologous HCT. In our study, the
average steroid dose, in prednisone equivalents through
day 1 100 post-HCT, was 4 mg per day in autologous
HCT patients, which is much lower than the average
19 mg per day in allogeneic HCT patients. The lack
of association of steroid dosewith BMD loss after autol-
ogous HCT may result from tolerance to low steroid
doses. Although there is no established safe corticoste-
roid dose threshold, 2 randomized trials showed virtu-
ally no change in bone density at the spine and hip in
rheumatoid arthritis patients receiving an average
steroid dose of 8 mg per day [28,29]. It is also possible
that corticosteroids received before transplantation as
part of induction and/or salvage therapy may have
extended their bone resorptive effects after autologous
HCT, which would dilute the association between
post-HCT steroid exposure and BMD loss. The acute
post-HCT bone loss observed among autologous
HCTpatientsmaybea combinedeffectofpretransplant
steroid exposure and other HCT-related risk factors.
Patients who had an autologousHCT forHodgkin
or non-Hodgkin lymphoma experienced significantly
more BMD loss at both the spine and hip thanmultiple
myeloma patients, whichwas confirmed inmultivariate
models. The reason for the difference in themagnitude
of bone loss between myeloma and lymphoma patients
may be from several factors. First, lymphoma patients
received a higher average daily steroid dose in the first
100 days post-HCT than MM patients, and received
different high-dose preparative regimens. Second,
skeletal complications are commonly seen in MM pa-
tients [30-32], due to an increased osteoclastic boneresorption and suppressed osteoblastic bone
formation from myeloma cells interacting with the
bone marrow microenvironment [33]. Although bone
lesions and hypercalcemia are rare in most lymphoma
patients [34], there are several reports indicating that
accelerated bone loss may be a common complication
of lymphoma therapy [35-38]. Third, MM patients
are frequently treated with bisphosphonates before
HCT, which may have extended protection against
post-HCTBMDloss.Finally,MMpatients hada lower
baseline BMD before transplantation compared to
lymphoma patients (mean T-score 20.20 veresus
10.20, respectively), because of their underlying ma-
lignancy or treatment for it. A previous study [6], as
well as our own, found a lower baseline BMDwas pro-
tective of bone loss post-HCT.
The significant BMD loss seen after autologous
HCTwas still lower than that after allogeneicHCT, es-
peciallywhen comparing the ratio of observed/expected
annual BMD loss rate between the 2 groups (Table 2).
The higher corticosteroid dose received by allogeneic
HCT patients may be one explanation for this differ-
ence and bisphosphonate treatment for myeloma
patients may be another. Nearly one-third of our autol-
ogous HCTs were myeloma patients, whereas none of
the allogeneicHCTpatients were treated for myeloma.
This subgroupof autologousHCTpatientsmay benefit
from the extended protection of bisphosphonate use
pre-HCT, which may partly explain the lower rate of
BMD loss seen in autologous versus allogeneic HCT
patients. As noted in the results, the differences in the
BMD loss rate between autologous and allogeneic
HCTs became smaller and nonsignificant after exclud-
ing the MM patients from the comparison.
Although the majority (70%) of our allogeneic
HCT patients RIC or NMA conditioning regimens,
the magnitude of BMD loss was comparable to prior
studies of patients who received MA regimens [6,7], and
conditioning regimen intensity was not significantly
associated with bone loss after allogeneic HCT. This
may be from the overwhelming effect of corticosteroid
exposure or that the threshold for chemotherapy-
associated bone destruction is lower than the reduced
intensity dose used prior to allogeneic HCT.
In our study, vitamin D supplementation was not
administered between the 2 DXA scans. Although it
has been hypothesized that vitamin D deficiency-
induced secondary hyperparathyroidism may be one
1136 Biol Blood Marrow Transplant 16:1130-1137, 2010S. Yao et al.reason for HCT-related BMD loss [39], trials of vita-
min D supplementation have failed to prevent bone
loss [12,14,19]. Our data also do not support a major
role of calcemic hormones including vitamin D and
PTH-mediated calcium homeostasis in the accelerated
bone loss after autologous or allogeneic HCT. It is
possible that the levels of the active vitamin D metab-
olite 1,25-dihydroxyvitaminDweremaintained within
normal range even though the major circulating
metabolite 25-OHD was low [40], resulting in undis-
turbed calcium homeostasis in most patients.
In summary, our prospective study found acceler-
ated BMD loss occurred commonly after both autolo-
gous and allogeneic HCT at a similar severity, but
because of different risk factors. Because antiresorptive
bisphosphonate therapy has been shown to effectively
prevent or reverse bone loss after allogeneic HCT, it is
highly warranted to evaluate similar strategies in
autologous HCT patients. More studies are needed
to evaluate individual risk of BMD loss before
transplantation.ACKNOWLEDGMENTS
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